News

Zydus Lifesciences has received permission to conduct a Phase III clinical trial of Desidustat for patients with sickle cell disease. Conducted in collaboration with the Indian Council of Medical Research (ICMR), the 203-day study will evaluate the efficacy and safety of Desidustat oral tablets in treating anemia. The trial will enrol 164 patients diagnosed with the disease. Sickle Cell Disease is a significant public health concern in India, especially among tribal populations where prevalence is higher. According to National Health Mission estimates, nearly 20 million people live with the condition, and roughly 50,000 children are born with sickle cell anaemia annually. While treatments like hydroxyurea and blood transfusions exist, their limited accessibility, inconsistent effectiveness, and associated risks remain significant challenges.

Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 11 August 2026.

Zydus Lifesciences and Guardant Health, Inc., a leading precision oncology company, have an exclusive agreement to make the Shield� Multi-Cancer Detection (MCD) test available in India, for which Zydus has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to offer the test in the territory. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older and who are at typical average risk for cancer. With just a blood draw, the test screens for 10 of the most common cancers, many of which have high mortality rates in India. The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), recognising its potential to provide more effective screening for cancers than existing options.

Zydus Lifesciences and Sunshine Healthcare today announced the setting up of a strategic joint venture company � Zydus Sunshine Lifesciences, with an investment commitment of over USD 20 million to establish a pharmaceutical manufacturing facility in Sri Lanka, strengthening local production and reducing import dependence. The facility, to be located at the Board of Investment zone in Horana, will be developed on nearly four acres of land. The foundation stone was laid today, marking the formal commencement of the project. The plant will focus on manufacturing pharmaceutical products for Sri Lanka`s retail market, improving access to high-quality medicines while supporting national supply chain resilience.The joint venture combines Zydus` global expertise in pharmaceutical manufacturing and technical know-how with Sunshine`s strong local market presence and healthcare distribution capabilities. The partnership will support technology transfer, build local manufacturing capability, and create employment, contributing to the long-term development of Sri Lanka`s healthcare ecosystem. The initiative comes at a critical time as Sri Lanka prioritises domestic production in essential sectors. By strengthening local pharmaceutical manufacturing capacity, the venture is expected to enhance supply security, reduce reliance on imports, and improve the affordability and availability of medicines.

Zydus Lifesciences has received a Warning Letter from the United States Food and Drug Administration (USFDA) relating to its formula on manufacturing facility located at Baddi, Himachal Pradesh. The Warning Letter was issued in response to a request for records pursuant to sec on 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, and does not pertain to any onsite inspection of the facility by the USFDA. The communication references technical observations regarding the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements. The company added that the said Warning Letter will not impact current operations and supplies from the Baddi site. The Baddi manufacturing facility was last subjected to an on-site inspection by the USFDA in August 2025. Subsequent to the conclusion of the inspec on, the Company received the Establishment Inspection Report (EIR) in October 2025, with the final compliance status classified as Voluntary Ac on Indicated (VAI).